Cover image for Vol. 10 Issue 5

Editor-in-Chief: Natalia Ortúzar

Impact Factor: 3.046

ISI Journal Citation Reports © Ranking: 2013: 18/58 (Chemistry Medicinal); 75/256 (Pharmacology & Pharmacy)

Online ISSN: 1860-7187

Associated Title(s): Angewandte Chemie International Edition, Chemistry - A European Journal, Chemistry – An Asian Journal, ChemBioChem, Medicinal Research Reviews, Molecular Informatics

May 28, 2013

Development of new Antibiotics by GSK Gets $200 Million Boost from US Government

To support the development of new compounds in the fight against antibiotic resistance and bioterrorism, the US Department of Health and Human Services (HHS) has awarded GlaxoSmithKline up to $200 million in a first-of-its kind public–private agreement.

HHS will supply $40 million for the first 18 months of the project, and will provide up to $200 million provided the agreement between the US government and GSK is renewed over five years.

The government–private sector collaboration will permit funding to encompass GSK's antibacterial portfolio instead of being earmarked for a specific drug candidate, and will involve the study of drugs for the potential treatment of both conventional pathogens and those that pose a threat for their use in bioterrorism.

Many pharmaceutical companies have recently stopped antibacterial R&D efforts, citing scientific challenges and lower returns on investment. This naturally impedes the ability to treat bacterial infections and leads to vulnerability to biothreat pathogens. Such a public–private partnership should therefore be important in sustaining efforts in this area of medicinal chemistry.

Full details can be found in the recent GSK press release. Some recent relevant ChemMedChem articles include:

Identification and Characterization of Inhibitors of the Aminoglycoside Resistance Acetyltransferase Eis from Mycobacterium tuberculosis

The Importance of the trans-Enamine Intermediate as a β-Lactamase Inhibition Strategy Probed in Inhibitor-Resistant SHV β-Lactamase Variant

Structural Studies on 4,5-Disubstituted 2-Aminoimidazole-Based Biofilm Modulators that Suppress Bacterial Resistance to β-Lactams

3-Aryl-4-methyl-2-quinolones Targeting Multiresistant Staphylococcus aureus Bacteria

Design, Synthesis, and Antibacterial Activity of Demethylvancomycin Analogues against Drug-Resistant Bacteria

Your Comment...

[Browse more news]